世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

後部ブドウ膜炎: パイプラインレビュー 2016年下半期

Posterior Uveitis - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年10月US$2,000
シングルユーザライセンス
65

サマリー

Global Markets Directによる後部ブドウ膜炎のパイプラインレビューです。



Report Details

Posterior Uveitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Posterior Uveitis ? Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis ? Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Posterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Posterior Uveitis - Overview 7
Posterior Uveitis - Therapeutics under Development by Companies 8
Posterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Posterior Uveitis - Products under Development by Companies 12
Posterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Neuroptis Biotech 14
Oculis ehf 15
pSivida Corp. 16
Regeneron Pharmaceuticals Inc 17
Sandoz International GmbH 18
Santen Pharmaceutical Co., Ltd. 19
Posterior Uveitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
adalimumab biosimilar - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dexamethasone acetate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dexamethasone sodium phosphate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
EYS-606 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
fluocinolone acetonide SR - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NOP-3 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
sarilumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
sirolimus - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Posterior Uveitis - Dormant Projects 52
Posterior Uveitis - Discontinued Products 53
Posterior Uveitis - Product Development Milestones 54
Featured News & Press Releases 54
Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target 54
Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting 54
Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle 55
Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) 55
Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve 56
May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe 57
Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis 58
Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial 58
Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis 59
Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs 61
May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis 61
Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis 62
Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る